Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

75
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
75
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.5K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.5K
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.5K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.5K
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

72
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
72
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

68
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
68
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

93
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
93

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging neurological and cognitive symptoms in patients with late-onset ornithine transcarbamylase deficiency: a narrative review.

Metabolic brain disease·2026
Same author

Exploring Sex and Clinical Factors Associated with Long-Term Survival After Implantable Cardioverter-Defibrillator Implantation: A 10-Year Cohort Study.

Journal of clinical medicine·2026
Same author

Readability Analysis of Commonly Cited Patient-Reported Outcome Measures in the Orthopaedic Joint Literature.

Arthroplasty today·2026
Same author

Transforming One Health in India: National Multisectoral Mixed Method Study on Prioritization of Zoonotic Diseases.

JMIR public health and surveillance·2025
Same author

Pesticides and habitat loss additively reduce wild bees in crop fields.

Nature ecology & evolution·2025
Same author

Internalized Binegativity and Alcohol Expectancies Following an Experience of Binegativity: An Experimental Study.

Journal of studies on alcohol and drugs·2025
Same journal

Brexpiprazole for anxiety symptoms in people living with schizophrenia: a plain language summary.

Expert review of clinical pharmacology·2026
Same journal

The systems medicine view of semaglutide: from clinical trials to molecular mechanisms.

Expert review of clinical pharmacology·2026
Same journal

Beyond snapshot dosing: a dynamic living digital twin framework for model-informed precision dosing in critical illness.

Expert review of clinical pharmacology·2026
Same journal

Understanding the relationship between aripiprazole levels in the blood and recurrence of mood episodes in people diagnosed with bipolar I disorder treated with a once-monthly injection of aripiprazole monohydrate: a plain language summary.

Expert review of clinical pharmacology·2026
Same journal

Tirzepatide in type 1 diabetes: beyond mere weight loss.

Expert review of clinical pharmacology·2026
Same journal

Prophylaxis for inherited factor X deficiency: a systematic review.

Expert review of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Mar 3, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

759

Dapsone-associated fixed drug eruption.

Daniel Garcia1, Philip R Cohen2

  • 1a School of Medicine , University of California San Diego , La Jolla , CA , USA.

Expert Review of Clinical Pharmacology
|April 25, 2017
PubMed
Summary
This summary is machine-generated.

Dapsone can cause fixed drug eruption, a skin reaction, particularly in regions with high leprosy treatment rates. Consider dapsone in patients with fixed drug eruption, especially those with multiple lesions on darker skin.

Keywords:
Dapsoneadverse cutaneous drug reactionadverse effectdermatologydrug reactionfixed drug eruption

More Related Videos

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

1.3K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.9K

Related Experiment Videos

Last Updated: Mar 3, 2026

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

759
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

1.3K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.9K

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Dapsone is a sulfone drug utilized for infectious and dermatologic conditions.
  • Fixed drug eruption (FDE) is a specific adverse cutaneous drug reaction.
  • FDE recurs upon re-exposure to the causative agent.

Purpose of the Study:

  • To review literature on dapsone-associated fixed drug eruption (DFDE).
  • To highlight characteristics and diagnostic considerations of DFDE.

Main Methods:

  • Literature search using keywords: dapsone, fixed drug eruption, adverse cutaneous drug reaction.
  • Review of bibliographies and relevant articles.
  • Inclusion of studies specifically on dapsone-associated FDE.

Main Results:

  • Most DFDE cases originate from Africa and India, linked to leprosy treatment.
  • DFDE shares characteristics with FDE in Western literature.
  • Differences noted in solitary versus multiple lesion frequency.
  • Multiple lesions may be more prevalent in darker-pigmented individuals.

Conclusions:

  • DFDE should be considered in patients presenting with FDE, especially those with a history of dapsone use.
  • Multiple DFDE lesions can mimic other conditions, such as Kaposi's sarcoma in HIV-positive patients.
  • DFDE is an important consideration in the differential diagnosis of multiple hyperpigmented lesions.